Introduction Dupilumab is a human monoclonal antibody that targets both IL-4 and IL-13
signaling. It is currently indicated for the treatment of asthma, moderate-to-severe atopic …

With the increasing number of options for the treatment of moderate‐to‐severe atopic
dermatitis, clinicians need guidance on a practical approach to selecting a systemic agent …

Atopic dermatitis is a heterogeneous disease and resists classification. In this review, we
discuss atopic dermatitis nomenclature and identify morphologic phenotypes, which will …

Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus, characterized by
recurrent eczema with exacerbations and remissions. AD impairs patients' QOL and places …

Background The management of paediatric atopic dermatitis (AD) is challenging, mostly
relying on emollients and topical corticosteroids. Dupilumab, a fully human monoclonal …

Background Evaluation of effectiveness and safety of new systemic treatments for atopic
dermatitis (AD) after approval is important. There are few published data exceeding 52 …

Background: Dupilumab is the first approved IL-4Rα inhibitor for the treatment of atopic
dermatitis at present with good efficacy and safety. However, there have been several …

Abstract Background Special populations (SPs) involve people who require additional
consideration in clinical research. Effectiveness of treatment or occurrence of side effects …

Background Biologics are currently one of the main treatment options for a number of
diseases. The IgG4 monoclonal antibody dupilumab targets the Interleukin-4 receptor alpha …

Background Moderate‐to‐severe atopic dermatitis (AD) in the adolescence is a high burden
disease, and its treatment can be very challenging due to paucity of approved systemic …